html5-img
1 / 41

Yves DEUGNIER

Yves DEUGNIER. HCV and iron The middle age ? Yves Deugnier Dominique Guyader Liver Unit & CIC Inserm 0203 Rennes - France PHC - Paris 22 & 23/01/07. Blumberg BS et al, PNAS 1979;76:2438-41. IRON. 1991-2007 = 527 studies. HCV. Iron status in HCV infected patients. IRON. HCV.

wendyl
Télécharger la présentation

Yves DEUGNIER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Yves DEUGNIER

  2. HCV and iron The middle age ? Yves Deugnier Dominique Guyader Liver Unit & CIC Inserm 0203 Rennes - France PHC - Paris 22 & 23/01/07

  3. Blumberg BS et al, PNAS 1979;76:2438-41

  4. IRON 1991-2007 = 527 studies HCV

  5. Iron status in HCV infected patients IRON HCV

  6. Serum iron-related indices in CHC Di Bisceglie AM, Gastroenterology 1992;102:2108-13 Alla V, Sem Liver Dis 2005;25:461-72

  7. Hepatic iron-related indices in CHC Hepatic iron concentration 10 - 36 % Slight increase (x 1.5 - 3 N) Mesenchymal deposition Except in cirrhosis Di Bisceglie AM, Gastroenterology 1992;102:2108-13 Alla V, Sem Liver Dis 2005;25:461-72

  8. Distribution of hepatic iron deposits in CHC Hepatocytic 34% Mesenchymal 12% Mixed 54% Guyader D, J Hepatol 2007 [Epub ahead of print]

  9. Distribution of hepatic iron deposits in CHC Hepatocytic 34% Deugnier Y, Am J Surg Pathol 1997 Ludwig J, Gastroenterology 1997

  10. Relationship between iron-related indices in CHC 46% 46% Guyader D, J Hepatol 2007 [Epub ahead of print]

  11. Direct Iron status in HCV infected patients IRON Mechanisms HCV

  12. Clinical data • No well-designed comparative study of iron status in various chronic liver diseases • Prevalence and type of abnormalities of iron-related indices roughly similar in CHC, NASH and ASH Bonkovsky HL, Hepatology 1997;25:759-768 Alla V, Sem Liver Dis 2005;25:461-472

  13. Biological data Homology between HCV and iron protein biology 5’ Internal Ribosome Entry Site = 5’ Iron Responsive Elements Synergism / competition between HFE and HCV HCV-induced modification in HFE metabolism ? HFE as a non classical MHC molecule hCMV US2 degradation of HFE in human and mouse cells Upregulation of TfR1 by HCV ? Ben-Arieh SV, J Virol 2001;75:10557-62 Saito H, Hepatology Res 2005;31:203-10 Spahn CM, Science 2001;291:1959-62

  14. Direct Iron status in HCV infected patients IRON Mechanisms Indirect Hyperferritinemia <> hepatic iron HCV

  15. Serum ferritin in chronic hepatitis C • Liver damage • Hepatic iron Serum ferritin Di Bisceglie AM, Gastroenterology 1992;102:2108-13

  16. Serum ferritin in chronic hepatitis C • Liver damage • Hepatic iron Associated factors • Age • Sex • Alcohol consumption • Metabolic syndrome • Steatosis • Thyroïditis, PCT… Serum ferritin Bonkovsky HL, Hepatology 1997;25:759-768 Alla V, Sem Liver Dis 2005;25:461-472

  17. Hepatic iron in chronic hepatitis C • Liver damage Inconstant correlation Hepatic iron METAVIR A METAVIR F Guyader D, J Hepatol 2007 [Epub ahead of print]

  18. Increased hepatic iron content in cirrhosis Hepatic insufficiency Transferrin Hepcidin Alcohol Tf NTBI TS Fe Stuart KA, Gastroenterology 2004;39:492-7 Detivaud L, Blood 2005;106:746-8 Bridle KR, Alc Clin Exp Res 2006;30:106-112

  19. Hepatic iron in chronic hepatitis C • Liver damage • Antiviral drugs • Duration of infection Associated factors • Age and sex • Alcohol consumption • Metabolic syndrome • PCT • HFE mutations Hepatic iron Bonkovsky HL, Hepatology 1997;25:759-768 Alla V, Sem Liver Dis 2005;25:461-472

  20. Prevalence of HFE mutations in CHC Aggravative effect on CHC ? ? C282Y ++ & compound heterozygotes Excluded Included N C282Y & H63D prevalence Vs controls Piperno A, Hepatology 1998 - Smith BC, Hepatology 1998 - Hézode C, J Hepatol 1999 - Fontana RJ, Hepatology 2000 - Kazemi-Shirazi, Gastroenterology 1999 - Martinelli AL, Acta Haematol 2000 - Negro F, J Med Virol 2000 - Pirisi M, Am J Clin Pathol, 2000 - Bonkovsky HL, J Hepatol 2002. Diwakaran HH, J Hepatol 2002 - Thung BY, Gastroenterology 2003 - Bonkowsky H, Gastroenterology 2006

  21. Serum iron-related indices C282Y H63D Hepatic iron deposition HFE genotypes and iron status in CHC Inclusion bias Small samples Confounding factors Piperno A, Hepatology 1998 - Smith BC, Hepatology 1998 - Kazemi-Shirazi, Gastro enterology 1999 - Martinelli AL, Acta Haematol 2000 - Negro F, J Med Virol 2000 - Pirisi M, Am J Clin Pathol, 2000 - Bonkovsky HL, J Hepatol 2002 - Thorburn D, Gut 2002 - Tung BY, Gastroenterology 2003 - Bonkowsky H Gastroenterology 2006.

  22. Direct Indirect Iron status in HCV infected patients IRON Mechanisms HCV

  23. Effects of iron on HCV replication HCV IRES EMCV IRES HCV 3’UTR NPT II NS3 NS4A NS4B NS5A NS5B HCV subgenomic replicon Huh 7 cells Fillebeen C, JBC 2005;280:9049-9057

  24. Direct Indirect Iron status in HCV infected patients IRON Mechanisms Liver damage Hepatitis course HCV

  25. Iron as an aggravating factor for fibrosis in CHC Biological evidence Hepatic iron ROS Fibrosis progression Fujita N, Free Rad Biol Med 2007;42:353-62

  26. Iron as an aggravating factor for fibrosis in CHC Clinical relevance Hepatic iron ? Fibrosis progression Pietrangelo A, Gastroenterology 2003;124:1509-23 Guyader D, J Hepatol 2007 [Epub ahead of print]

  27. Iron as an aggravating factor for fibrosis in CHC Male sex Age at contamination > 40 y Duration of infection Daily alcohol consumption > 50 g Necroinflammatory activity Steatosis Metabolic syndrome HFE mutations Clinical relevance Hepatic iron ? Fibrosis progression Pietrangelo A, Gastroenterology 2003;124:1509-23 Guyader D, J Hepatol 2007 [Epub ahead of print]

  28. Effects of phlebotomies in chronic hepatitis C Phlebotomies Serum transaminases Necroinflammatory activity Fibrosis progression Risk of cancer Hayashi H, Am J Gastroenterol 1994 & J Hepatol 1995 - Fong TL, J Hepatol 1998 - Guyader D, Am J Gastroenterol 1999 - Fontana RJ, Hepatology 2000 - Di Bisceglie AM, Hepatology 2000 - Yano M, AJGE 2002.

  29. Effects of phlebotomies in chronic hepatitis C Phlebotomies No effect on viral load Hayashi H, Am J Gastroenterol 1994 & J Hepatol 1995 - Fong TL, J Hepatol 1998 - Guyader D, Am J Gastroenterol 1999 - Fontana RJ, Hepatology 2000 - Di Bisceglie AM, Hepatology 2000 - Yano M, AJGE 2002.

  30. Direct Indirect Iron status in HCV infected patients IRON Mechanisms Fibrosis Hepatitis course Cancer HCV

  31. Increased hepatic iron and cancer risk Transferrin Hepcidin Tf NTBI TS Fe Lipid peroxidation DNA damage Turlin B, Hepatology 1995 Deugnier Y, Alcohol 2003

  32. FL-N/35 transgenic* mouse *polyprotein-coding region of HCV 1b Diet with either normal (45 mg/kg) or excessive iron (225 mg/kg) content (carbonyl iron - CI) for 12 months Furutani T, Gastroenterology 2006;130:2087-98

  33. Fibrosis Cancer Iron status in HCV infected patients IRON Direct Mechanisms Indirect Hepatitis course HCV Response to therapy

  34. Hepatic iron and response to antiviral therapy Prediction of poor SVR IFN Increased HIC Mesenchymal iron PEG + RBV Endothelial iron Mesenchymal iron Olynyk J, Gastroenterology 1995;108:1104-9 Barton AL, Am J Clin Pathol 1995;103:419-24 Rulyak SJ, Am J Gastroenterol 2005;100:332-7 Bonkowsky H, Gastroenterology 2006;131:1440-51

  35. Effects of phlebotomies on response to therapy Antiviral therapy + Phlebotomies No effect on sustained virological response Hayashi H, Am J Gastroenterol 1994 & J Hepatol 1995 - Fong TL, J Hepatol 1998 - Guyader D, Am J Gastroenterol 1999 - Fontana RJ, Hepatology 2000 - Di Bisceglie AM, Hepatology 2000 - Yano M, AJGE 2002.

  36. Effect of HFE mutations on virological response rate HALT C study - 1145 NR C282Y H63D S65C Bonkowsky H, Gastroenterology 2006;131:1440-51 Distante S, Liver 2002;22:269-75 (SVR - C282Y) Lebray P, J Viral Hepat 2004;11:175-82 (VR - H63D)

  37. IRON Iron proteins HFE mutations Liver damage Antiviral drugs Diet, alcohol PCT, MS… ROS Immune fcts HCV Disease progression (fibrosis, cancer…) Response to therapy

  38. Alcohol, PCT Thyroïditis Inflammation Metabolic syndrome… Hyperferritinemia <> Increased hepatic iron Direct assessment of hepatic iron

  39. Indication of phlebotomies + Avoid to induce anemia in order not to impair compliance to antiviral Tt

  40. HCV and iron The middle age ? Yves Deugnier Dominique Guyader Liver Unit & CIC Inserm 0203 Rennes - France PHC - Paris 22 & 23/01/07

More Related